PURPOSE: To evaluate the ability of a new combined biomechanical index called the Corvis Biomechanical Index (CBI) based on corneal thickness profile and deformation parameters to separate normal from keratoconic patients. METHODS: Six hundred fifty-eight patients (329 eyes in each database) were included in this multicenter retrospective study. Patients from two clinics located on different continents were selected to test the capability of the CBI to separate healthy and keratoconic eyes in more than one ethnic group using the Corvis ST (Oculus Optikgeräte GmbH, Wetzlar, Germany). Logistic regression was employed to determine, based on Database 1 as the development dataset, the optimal combination of parameters to accurately separate normal from keratoconic eyes. The CBI was subsequently independently validated on Database 2. RESULTS: The CBI included several dynamic corneal response parameters: deformation amplitude ratio at 1 and 2 mm, applanation 1 velocity, standard deviation of deformation amplitude at highest concavity, Ambrósio's Relational Thickness to the horizontal profile, and a novel stiffness parameter. The receiver operating characteristic curve analysis of the training database showed an area under the curve of 0.983. With a cut-off value of 0.5, 98.2% of the cases were correctly classified with 100% specificity and 94.1% sensitivity. In the validation dataset, the same cut-off point correctly classified 98.8% of the cases with 98.4% specificity and 100% sensitivity. CONCLUSIONS: The CBI was shown to be highly sensitive and specific to separate healthy from keratoconic eyes. The presence of an external validation dataset confirms this finding and suggests the possible use of the CBI in everyday clinical practice to aid in the diagnosis of keratoconus. [ J Refract Surg. 2016;32(12):803–810.]

Background: Optimal doses of iv glucocorticoids for Graves' orbitopathy (GO) are undefined. Methods: We carried out a multicenter, randomized, double-blind trial to determine efficacy and safety of three doses of iv methylprednisolone in 159 patients with moderate to severe and active GO. Patients were randomized to receive a cumulative dose of 2.25, 4.98, or 7.47 g in 12 weekly infusions. Efficacy was evaluated objectively at 12 wk by blinded ophthalmologists and subjectively by blinded patients (using a GO specific quality of life questionnaire). Adverse events were recorded at each visit. Results: Overall ophthalmic improvement was more common using 7.47 g (52%) than 4.98 g (35%; P = 0.03) or 2.25 g (28%; P = 0.01). Compared with lower doses, the high-dose regimen led to the most improvement in objective measurement of ocular motility and in the Clinical Activity Score. The Clinical Activity Score decreased in all groups and to the least extent with 2.25 g. Quality of life improved most in the 7.47-g group, although not reaching statistical significance. No significant differences occurred in exophthalmos, palpebral aperture, soft tissue changes, and subjective diplopia score. Dysthyroid optic neuropathy developed in several patients in all groups. Because of this, differences among the three groups were no longer apparent at the exploratory 24-wk visit. Major adverse events were slightly more frequent using the highest dose but occurred also using the lowest dose. Among patients whose GO improved at 12 wk, 33% in the 7.47-group, 21% in the 4.98-group, and 40% in the 2.25-group had relapsing orbitopathy after glucocorticoid withdrawal at the exploratory 24-wk visit. Conclusions: The 7.47-g dose provides short-term advantages over lower doses. However, this benefit is transient and associated with slightly greater toxicity. The use of a cumulative dose of 7.47 g of methylprednisolone provides short-term advantage over lower doses. This may suggest that an intermediate-dose regimen be used in most cases and the high-dose regimen be reserved to most severe cases of GO.

The prevalence and natural history of Graves' orbitopathy (GO) are poorly documented. A large series of 346 patients with newly diagnosed and recent onset Graves' hyperthyroidism seen at a single (nontertiary referral) center over an 8-year period were enrolled in an observational prospective study and evaluated for GO activity and severity according to the EUGOGO (European Group on Graves' Orbitopathy) criteria. After excluding patients immediately treated for moderate-to-severe GO, patients undergoing total thyroidectomy or radioactive iodine treatment, and patients lost to follow-up, 237 patients were submitted to antithyroid drug (ATD) treatment, with ocular evaluation at 6, 12, and 18 months. Among the whole cohort, at presentation 255 (73.7%) had no ocular involvement, 70 (20.2%) had mild and inactive GO, 20 (5.8%) had moderate-to-severe and active GO, and 1 (0.3%) had sight-threatening GO with dysthyroid optic neuropathy. Of the 237 patients who completed the 18-month follow-up during or after ATD treatment, 194 (81.9%) had no GO at baseline. Progression to moderate-to-severe GO occurred in 5 (2.6%) of these patients. Of the 43 (18.1%) patients with mild and inactive GO at baseline, 1 (2.4%) progressed to moderate-to-severe GO, and 25 (58.1%) experienced complete remission. Most patients with newly diagnosed Graves' disease have no ocular involvement. Moderate-to-severe and active GO or sight-threatening GO are rare at presentation and rarely develop during ATD treatment. Most patients (>80%) with no GO at baseline do not develop GO after an 18-month follow-up period. Remission of mild GO occurs in the majority of cases.

PURPOSE: To evaluate the influence of pachymetry, age, and intraocular pressure in normal patients and to provide normative values for all dynamic corneal response parameters (DCRs) provided by dynamic Scheimpflug analysis. METHODS: Seven hundred five healthy patients were included in this multicenter retrospective study. The biomechanical response data were analyzed to obtain normative values with their dependence on corrected and clinically validated intraocular pressure estimates developed using the finite element method (bIOP), central corneal thickness (CCT), and age, and to evaluate the influence of bIOP, CCT, and age. RESULTS: The results showed that all DCRs were correlated with bIOP except deflection amplitude (DefA) ratio, highest concavity (HC) radius, and inverse concave radius. The analysis of the relationship of DCRs with CCT indicated that HC radius, inverse concave radius, deformation amplitude (DA) ratio, and DefA ratio were correlated with CCT (rho values of 0.343, −0.407, −0.444, and −0.406, respectively). The age group subanalysis revealed that primarily whole eye movement followed by DA ratio and inverse concave radius were the parameters that were most influenced by age. Finally, custom software was created to compare normative values to imported examinations. CONCLUSIONS: HC radius, inverse concave radius, DA ratio, and DefA ratio were shown to be suitable parameters to evaluate in vivo corneal biomechanics due to their independence from IOP and their correlation with pachymetry and age. The creation of normative values allows the interpretation of an abnormal examination without the need to match every case with another normal patient matched for CCT and IOP. [ J Refract Surg . 2016;32(8):550–561.]

PURPOSE: To present a case series of patients with subclinical keratoconus with normal topometric (anterior curvature) and tomographic findings in one eye who showed abnormalities detected by Corvis ST (Oculus Optikgeräte GmbH, Wetzlar, Germany) in vivo biomechanical assessment. METHODS: All patients had a complete ophthalmic examination, including the Corvis ST biomechanical measurements, optical tomography, and pachymetry with Pentacam (Oculus Optikgeräte GmbH), and Placido-based topography with either the Nidek (OPD III Nidek, Gamagori, Japan) or CSO platform (Costruzione Strumenti Oftalmici, Florence, Italy). Inclusion criteria were a clinical diagnosis of ectasia in one eye and normal topometric and tomographic findings in the fellow eye (subclinical keratoconus), including a Belin/Ambrósio Enhanced Ectasia total deviation index from the Pentacam with less than 1.6 standard deviations from normative values and a Corvis Biomechanical Index score of greater than 0.5 in both eyes. RESULTS: Tomographic and topographic analysis was normal in one eye and abnormal in the fellow eye in 12 patients. The biomechanical results with the Corvis Biomechanical Index were shown to be abnormal in both eyes of all patients and aided the diagnosis. CONCLUSIONS: Biomechanical analysis showed abnormalities, whereas tomography and topography were normal. Basing on these findings, the authors suggest the use of biomechanics as an additional diagnostic tool. [ J Refract Surg. 2017;33(6):399–407.]